MEB Stock Overview
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MedinCell S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €10.78 |
| 52 Week High | €11.16 |
| 52 Week Low | €5.51 |
| Beta | 1.15 |
| 1 Month Change | 16.54% |
| 3 Month Change | 35.09% |
| 1 Year Change | 20.85% |
| 3 Year Change | -0.92% |
| 5 Year Change | 73.31% |
| Change since IPO | 53.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 17.9% | -3.3% | -1.5% |
| 1Y | 20.9% | -30.8% | 0.9% |
Return vs Industry: MEB exceeded the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: MEB exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| MEB volatility | |
|---|---|
| MEB Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MEB's share price has been volatile over the past 3 months.
Volatility Over Time: MEB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 138 | Christophe Douat | www.medincell.com |
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company’s products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.
MedinCell S.A. Fundamentals Summary
| MEB fundamental statistics | |
|---|---|
| Market cap | €313.37m |
| Earnings (TTM) | -€26.42m |
| Revenue (TTM) | €14.13m |
22.2x
P/S Ratio-11.9x
P/E RatioIs MEB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEB income statement (TTM) | |
|---|---|
| Revenue | €14.13m |
| Cost of Revenue | €0 |
| Gross Profit | €14.13m |
| Other Expenses | €40.55m |
| Earnings | -€26.42m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Jun 25, 2024
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 100.00% |
| Net Profit Margin | -187.04% |
| Debt/Equity Ratio | -245.0% |
How did MEB perform over the long term?
See historical performance and comparison